England-based Ultromics’ AI technology could improve detection of cardiac amyloidosis on routine echocardiograms, according to a new study from the company.
The results were presented at the American Society of Echocardiography’s 2025 Scientific Sessions in Nashville, Tenn., and published in the Journal of the American Society of Echocardiography.
Cardiac amyloidosis, once considered rare, is increasingly recognized as a common cause of heart failure. New therapies can slow progression but are most effective when started early, though up to 66% of cases go undiagnosed, according to a Sept. 23 news release.
In a multicenter study of 4,815 patients across 17 hospitals in the U.S. and U.K., Ultromics’ EchoGo Amyloidosis model improved referral accuracy over traditional measures. AI raised correct referral rates from about 65% to up to 80% in low-prevalence settings, while also reducing unnecessary referrals by up to 18% in higher-prevalence scenarios.
“Too often, patients with cardiac amyloidosis are diagnosed only after years of unexplained symptoms and irreversible damage,” Ashley Akerman, MD, director of clinical sciences at Ultromics and lead study author, said in the release. “Our findings suggest that using EchoGo Amyloidosis to enhance routine heart scans, doctors could better identify at-risk patients, reduce unnecessary testing and ensure that those who need confirmatory diagnosis and treatment receive it sooner.”
The findings build on more than 25 peer-reviewed studies validating the EchoGo platform, which is FDA-cleared, Medicare-reimbursed and in use at U.S. hospitals, including UChicago Medicine.
